This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.
Subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures.
Age 18~70 years old.
Pathologically confirmed unresectable locally advanced/metastatic non-small cell lung cancer.
At least one measurable lesion per RECIST v1.1 criteria.
Active or symptomatic brain metastases.
Previous diagnosis of any other malignancy.
Clinically symptomatic moderate to severe ascites; Uncontrollable or moderate or above pleural effusion, pericardial effusion.
Received anti-tumor therapy 4 weeks prior to initiation of study treatment.